secwatch.observer — SEC 8-K summary
======================================

Issuer:     RxSight, Inc. (RXST)
CIK:        0001111485
Form:       8-K
Filed at:   2022-07-11T23:59:59+00:00
Accession:  0000950170-22-012611
Event type: regulatory
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

RxSight receives FDA request for additional info on lower-cost LDD; expects no timeline impact
--------------------------------------------------------------------------------

- FDA requested additional information for approval of lower-cost-to-manufacture Light Delivery Device (LDD).
- Commercial sale of the lower-cost LDD not planned until 2023; company believes it can meet the timeline.
- Lower-cost LDD has the same functionality as the currently marketed LDD.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1111485/000095017022012611/0000950170-22-012611-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1111485/000095017022012611/rxst-20220711.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-012611

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer